Drug intelligence / Profile preview

LZ-007

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

LZ-007 is a small molecule drug that acts as an agonist for the farnesoid X receptor (FXR). It is designed to reduce lipid metabolism issues and has shown potent effects against metabolic dysfunction-associated steatohepatitis (MASH) by regulating pathways related to lipid metabolism, oxidative stress, inflammation, and fibrosis[1][3].

Targets

FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on LZ-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LZ-007.

Explore the full profile